Company Description
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases.
The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.
In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN).
The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024.
Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Country | United States |
Founded | 2018 |
IPO Date | Aug 10, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 18 |
CEO | Aoife Brennan |
Contact Details
Address: 20 William Street, Suite 145 Wellesley Hills, Massachusetts 02481 United States | |
Phone | 866 857 2596 |
Website | climbbio.com |
Stock Details
Ticker Symbol | CLYM |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001768446 |
ISIN Number | US28658R1068 |
Employer ID | 83-2273741 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc | Chief Executive Officer, President and Director |
Dr. Brett Kaplan M.B.A., M.D. | Chief Operating Officer and Principal Financial Officer |
Emily Pimblett CPA | Senior Vice President of Finance and Chief Accounting Officer |
Dr. Nishi Rampal M.D. | Senior Vice President of Clinical Development |
Janaki M. Subramanyam M.Sc. | Vice President and Head of Regulatory Affairs |
Kate Hecht M.B.A. | Senior Vice President of Program Management |
Dr. Perrin Wilson B.S., Ph.D. | Chief Business Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 25, 2025 | ARS | Filing |
Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
Apr 1, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
Apr 1, 2025 | 8-K | Current Report |
Mar 25, 2025 | 8-K | Current Report |
Mar 25, 2025 | 424B5 | Filing |
Mar 25, 2025 | 10-K | Annual Report |
Feb 13, 2025 | SCHEDULE 13G/A | Filing |
Jan 10, 2025 | 8-K | Current Report |